Literature DB >> 25143189

Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients.

Akmal Safwat1, Anders Boysen, Arne Lücke, Philip Rossen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25143189     DOI： 10.3109/0284186X.2014.948062

Source DB:  PubMed          Journal:  Acta Oncol        ISSN： 0284-186X            Impact factor:   4.089


× No keyword cloud information.
  16 in total

1.  Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations.

Authors:  Yoshiyuki Suehara; Deepu Alex; Anita Bowman; Sumit Middha; Ahmet Zehir; Debyani Chakravarty; Lu Wang; George Jour; Khedoudja Nafa; Takuo Hayashi; Achim A Jungbluth; Denise Frosina; Emily Slotkin; Neerav Shukla; Paul Meyers; John H Healey; Meera Hameed; Marc Ladanyi
Journal:  Clin Cancer Res       Date:  2019-06-07       Impact factor: 12.531

2.  BMTP-11 is active in preclinical models of human osteosarcoma and a candidate targeted drug for clinical translation.

Authors:  Valerae O Lewis; Eswaran Devarajan; Marina Cardó-Vila; Dafydd G Thomas; Eugenie S Kleinerman; Serena Marchiò; Richard L Sidman; Renata Pasqualini; Wadih Arap
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-11       Impact factor: 11.205

Review 3.  Advances in the Treatment of Pediatric Bone Sarcomas.

Authors:  Patrick J Grohar; Katherine A Janeway; Luke D Mase; Joshua D Schiffman
Journal:  Am Soc Clin Oncol Educ Book       Date:  2017

Review 4.  Radiopharmaceuticals for Treatment of Osteosarcoma.

Authors:  Peter M Anderson
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 5.  Review of Osteosarcoma and Current Management.

Authors:  Ryan A Durfee; Maryam Mohammed; Hue H Luu
Journal:  Rheumatol Ther       Date:  2016-10-19

Review 6.  Anti-angiogenesis target therapy for advanced osteosarcoma (Review).

Authors:  Lu Xie; Tao Ji; Wei Guo
Journal:  Oncol Rep       Date:  2017-06-21       Impact factor: 3.906

7.  Prognostic impact of blood and urinary angiogenic factor levels at diagnosis and during treatment in patients with osteosarcoma: a prospective study.

Authors:  Marie-Dominique Tabone; Laurence Brugières; Sophie Piperno-Neumann; Marie-Ange Selva; Perrine Marec-Bérard; Hélène Pacquement; Cyril Lervat; Nadège Corradini; Jean-Claude Gentet; Rémy Couderc; Aurélie Chevance; Céline Mahier-Ait Oukhatar; Natacha Entz-Werle; Jean-Yves Blay; Marie-Cecile Le Deley
Journal:  BMC Cancer       Date:  2017-06-15       Impact factor: 4.430

Review 8.  Biology of Bone Sarcomas and New Therapeutic Developments.

Authors:  Hannah K Brown; Kristina Schiavone; François Gouin; Marie-Françoise Heymann; Dominique Heymann
Journal:  Calcif Tissue Int       Date:  2017-12-13       Impact factor: 4.333

9.  CT-morphologic and CT-textural patterns of response in inoperable soft tissue sarcomas treated with pazopanib-a preliminary retrospective cohort study.

Authors:  Michael Esser; Cristopher Kloth; Wolfgang M Thaiss; Christian P Reinert; Mareen S Kraus; Gabriel Cc Gast; Marius Horger
Journal:  Br J Radiol       Date:  2019-09-19       Impact factor: 3.039

10.  Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients.

Authors:  Robert M Conry; Michael G Rodriguez; Joseph G Pressey
Journal:  Clin Sarcoma Res       Date:  2016-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.